Standout Papers

Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial 2022 2026 2023 2024180
  1. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial (2022)
    Sattva S. Neelapu, Michael Dickinson et al. Nature Medicine

Immediate Impact

13 from Science/Nature 69 standout
Sub-graph 1 of 24

Citing Papers

Tailoring traditional Chinese medicine in cancer therapy
2025 Standout
Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors
2025 Standout
2 intermediate papers

Works of Matthew L. Ulrickson being referenced

Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial
2022 Standout
Sierra Clinical Trial Dosimetry Results Support Low Dose Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] for Targeted Lymphodepletion Prior to Adoptive Cell Therapy
2019

Author Peers

Author Last Decade Papers Cites
Matthew L. Ulrickson 301 149 63 76 32 381
Sami Ibrahimi 258 145 57 48 32 363
Pim Mutsaers 242 164 54 49 29 337
Alessandro Crotta 256 109 53 47 24 346
Alessandro Previtali 239 99 70 80 17 341
Marion Alcantara 249 138 115 99 24 383
Jay Y. Spiegel 234 97 41 93 28 348
David Sermer 207 98 91 109 22 364
Barbara S. Pender 362 139 102 100 19 432
Juying Wei 196 72 78 102 41 353
Victor A. Chow 205 74 48 79 29 344

All Works

Loading papers...

Rankless by CCL
2026